A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Public ClinicalTrials.gov record NCT01067521. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
Study identification
- NCT ID
- NCT01067521
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 1,404 participants
Conditions and interventions
Conditions
Interventions
- Glatiramer acetate (GA) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2010
- Primary completion
- May 7, 2012
- Completion
- May 11, 2017
- Last update posted
- Dec 8, 2021
2010 – 2017
United States locations
- U.S. sites
- 37
- U.S. states
- 17
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 1332 | Birmingham | Alabama | 35209 | — |
| Teva Investigational Site 1327 | Gilbert | Arizona | 85234 | — |
| Teva Investigational Site 1311 | Phoenix | Arizona | 85004 | — |
| Teva Investigational Site 1326 | Fullerton | California | 92835 | — |
| Teva Investigational Site 1335 | La Jolla | California | 92037 | — |
| Teva Investigational Site 1297 | Aurora | Colorado | 80045 | — |
| Teva Investigational Site 1344 | Boulder | Colorado | 80304 | — |
| Teva Investigational Site 1315 | Centennial | Colorado | 80112 | — |
| Teva Investigational Site 1350 | Fort Collins | Colorado | 80528 | — |
| Teva Investigational Site 1345 | Miami | Florida | 33136 | — |
| Teva Investigational Site 1336 | Naples | Florida | 34102 | — |
| Teva Investigational Site 1347 | Pompano Beach | Florida | 33060 | — |
| Teva Investigational Site 1319 | Ponte Vedra | Florida | 32082 | — |
| Teva Investigational Site 1298 | Sarasota | Florida | 34233 | — |
| Teva Investigational Site 1316 | Sarasota | Florida | 34239 | — |
| Teva Investigational Site 1340 | Tampa | Florida | 33606 | — |
| Teva Investigational Site 1317 | Vero Beach | Florida | 32960 | — |
| Teva Investigational Site 1303 | Northbrook | Illinois | 60062 | — |
| Teva Investigational Site 1334 | Lenexa | Kansas | 66214 | — |
| Teva Investigational Site 1302 | Lexington | Kentucky | 40513 | — |
| Teva Investigational Site 1322 | Shreveport | Louisiana | 71103 | — |
| Teva Investigational Site 1306 | Detroit | Michigan | 48201 | — |
| Teva Investigational Site 1329 | Akron | Ohio | 44320 | — |
| Teva Investigational Site 1349 | Columbus | Ohio | 43221 | — |
| Teva Investigational Site 1313 | Dayton | Ohio | 45417 | — |
| Teva Investigational Site 1318 | Uniontown | Ohio | 44685 | — |
| Teva Investigational Site 1341 | Oklahoma City | Oklahoma | 73104 | — |
| Teva Investigational Site 1310 | Nashville | Tennessee | 37205 | — |
| Teva Investigational Site 1321 | Lubbock | Texas | 79410 | — |
| Teva Investigational Site 1337 | Round Rock | Texas | 78681 | — |
| Teva Investigational Site 1301 | San Antonio | Texas | 78231 | — |
| Teva Investigational Site 1346 | San Antonio | Texas | 78258 | — |
| Teva Investigational Site 1343 | Salt Lake City | Utah | 84106 | — |
| Teva Investigational Site 1338 | Richmond | Virginia | 23298-0599 | — |
| Teva Investigational Site 1339 | Roanoke | Virginia | 24018 | — |
| Teva Investigational Site 1300 | Vienna | Virginia | 22182 | — |
| Teva Investigational Site 1323 | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 139 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01067521, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2021 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01067521 live on ClinicalTrials.gov.